当前位置：首页 > 文献互助 > 互助详情

Oral epinastine vs loratadine in seasonal allergic rhinitis: A randomized, double‑blind, placebo‑controlled trial复制

用户dtTypm8xY_dg 12分钟前 10 10 已关闭

DOI:复制

文献链接:复制

其他信息:

Bielory L, et al. Oral epinastine vs loratadine in seasonal allergic rhinitis: A randomized, double‑blind, placebo‑controlled trial. Clin Ther. 2001;23(8):1129-1143.
DOI: 10.1016/S0140-6736(01)00561-3

上一篇：Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS

下一篇：Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference

互助时间线

2026-05-26 11:26:01 [关闭求助]

系统关闭了求助

备注: 无法查找到相关文献信息

2026-05-26 11:16:56 [发起求助]

最新发布的求助

Hydrophilic nano-SiO2/PVA-based coating with durable antifogging properties 41秒前
Trial of the Oral PCSK9 Inhibitor Enlicitide. Reply 8分钟前
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference 10分钟前
Oral epinastine vs loratadine in seasonal allergic rhinitis: A randomized, double‑blind, placebo‑controlled trial 12分钟前
Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS 15分钟前
Phase 3 study results for oral PCSK9 inhibition with enlicitide 15分钟前
Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. 23分钟前
Enantioselective Copper-Catalyzed Construction of Aryl Pyrroloindolines via an Arylation–Cyclization Cascade 26分钟前
Intratonsillar Immunotherapy: A Convenient and Effective Alternative to Subcutaneous Immunotherapy for Allergic Rhinitis 33分钟前
The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism 35分钟前
Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation 40分钟前
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial 51分钟前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com